Cargando…
Cancer-Associated Thrombosis: Risk Assessment, Prevention, and Treatment
The risk of developing venous thromboembolism (VTE) is four to seven times higher in patients with cancer than in those without. At JADPRO Live 2022, presenters discussed risk factors and assessing patients for VTE, as well as how to protect patients against VTE in both the inpatient and outpatient...
Autores principales: | Halsema, Keri, Mcmahon, Brandon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184841/ https://www.ncbi.nlm.nih.gov/pubmed/37197728 http://dx.doi.org/10.6004/jadpro.2023.14.3.6 |
Ejemplares similares
-
Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia
por: Samuels, Courtney, et al.
Publicado: (2021) -
Direct Oral Anticoagulants and Cancer Thrombosis: What APs Need to Know
por: Wilks, Mailey L.
Publicado: (2022) -
Cancer-associated thrombosis: prevention and treatment
por: Brose, K.M.J., et al.
Publicado: (2008) -
Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination
por: Buoninfante, Alessandra, et al.
Publicado: (2022) -
Getting to zero the biomedical way in Africa: outcomes of deliberation at the 2013 Biomedical HIV Prevention Forum in Abuja, Nigeria
por: Folayan, Morenike Oluwatoyin, et al.
Publicado: (2014)